PSMA摄取与肿瘤血流联合预测前列腺癌侵袭性的潜在协同作用
回顾性纳入43例接受[68Ga]Ga-PSMA-11 PET临床检查的前列腺癌患者,分析52个病灶的PSMA与[82Rb]Rb肿瘤血流量(TBF)SUVmax。两者与ISUP分级分组中度相关且相互相关;联合模型区分ISUP GG>2与GG1-2及良性病灶的AUC为0.85,灵敏度96%、特异度74%、阴性预测值95%,显著优于单用任一示踪剂。
要点
- PSMA摄取与肿瘤血流均与ISUP分级分组中度相关,联合可互补。
- 联合模型区分有临床意义前列腺癌的AUC为0.85、阴性预测值95%。
- 联合模型较单用示踪剂显著减少假阴性。
核心结论
- PSMA摄取与肿瘤血流提供关于肿瘤侵袭性的互补信息,联合分析可能提高阴性预测值并无创区分有临床意义与无临床意义前列腺癌。
研究设计与样本
- 回顾性研究,从既往[82Rb]Rb PET肿瘤血流研究中选择43例接受临床[68Ga]Ga-PSMA-11 PET的前列腺癌患者,分析52个病灶的ISUP分级分组。
主要发现
- [68Ga]Ga-PSMA-11 SUVmax与ISUP分级分组中度相关(rho=0.59,p<0.001)。
- [82Rb]Rb SUVmax与ISUP分级分组中度相关(rho=0.56,p<0.001)。
- 两种示踪剂SUVmax相互中度相关(r=0.65,p<0.001)。
- 联合模型区分ISUP GG>2与GG1-2及良性病灶的AUC为0.85,灵敏度96%、特异度74%、阴性预测值95%。
- 联合模型显著优于单用任一示踪剂(p<0.001),主要将假阴性从5或6例降至1例(p≤0.025)。
关键数值与推荐
- 联合模型以[68Ga]Ga-PSMA-11与[82Rb]Rb SUVmax区分ISUP GG>2与GG1-2及良性病灶的AUC为0.85。
- 联合模型灵敏度96%、特异度74%、阴性预测值95%。
临床怎么用
- 对前列腺癌病灶可联合评估PSMA摄取与肿瘤血流,以提高排除有临床意义前列腺癌的阴性预测值。
局限性
- 回顾性研究,样本来自既往[82Rb]Rb PET研究中选择接受临床PSMA PET的患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both prostate-specific membrane antigen (PSMA) uptake and tumour blood flow (TBF) correlate with International Society of Urological Pathology (ISUP) Grade Group (GG) and hence prostate cancer (PCa) aggressiveness. The aim of the present study was to evaluate the potential synergistic benefit of combining the two physiologic parameters for separating significant PCa from insignificant findings. METHODS: From previous studies of [82Rb]Rb positron emission tomography (PET) TBF in PCa, the 43 patients that underwent clinical [68Ga]Ga-PSMA-11 PET were selected for this retrospective study. Tumours were delineated on [68Ga]Ga-PSMA-11 PET or magnetic resonance imaging. ISUP GG was recorded from 52 lesions. RESULTS: [68Ga]Ga-PSMA-11 maximum standardized uptake value (SUVmax) and [82Rb]Rb SUVmax correlated moderately with ISUP GG (rho = 0.59 and rho = 0.56, both p < 0.001) and with each other (r = 0.65, p < 0.001). A combined model of [68Ga]Ga-PSMA-11 and [82Rb]Rb SUVmax separated ISUP GG > 2 from ISUP GG 1-2 and benign with an area-under-the-curve of 0.85, 96% sensitivity, 74% specificity, and 95% negative predictive value. The combined model performed significantly better than either tracer alone did (p < 0.001), primarily by reducing false negatives from five or six to one (p ≤ 0.025). CONCLUSION: PSMA uptake and TBF provide complementary information about tumour aggressiveness. We suggest that a combined analysis of PSMA uptake and TBF could significantly improve the negative predictive value and allow non-invasive separation of significant from insignificant PCa.
引用
- Jochumsen MR, Sörensen J, Tolbod LP, et al. Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness. EJNMMI Res. 2021. PMID: 33559792. doi:10.1186/s13550-021-00757-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。